The use of immune checkpoint inhibitors (ICIs) improves the prognosis of patients with advanced non-small cell lung cancer (NSCLC). However, some patients still fail to benefit from them. In recent years, studies have demonstrated that the combination of antiangiogenic agents with ICIs can enhance the antitumor effect, and guidelines at home and abroad have suggested that the combination of ICIs with antiangiogenic regimens can be used in patients with advanced NSCLC. Therefore, the mechanism of action and the latest clinical studies on the combination of ICIs and anti-angiogenic drugs in the treatment of advanced NSCLC were reviewed in this article to provide reference for treating advanced NSCLC.